Efficacy and Potential Mechanism of Gelanxinning Soft Capsules in Patients with Coronary Microvascular Dysfunction: A Randomized Controlled Trial

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ITMCTR

Registry ID

ITMCTR2026000943

Enrollment

Unknown

Registered

2026-04-12

Start date

2026-03-10

Completion date

Unknown

Last updated

2026-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary microvascular dysfunction

Interventions

experimental group:Conventional Western medical treatment+Gexingning soft Capsules

control group:Conventional Western medical treatment

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Aged between 18 and 80 years, with no restrictions on gender or general condition; voluntarily participate in this study and sign the informed consent form. (2) Diagnosed with coronary atherosclerotic heart disease, with coronary angiography or coronary CT angiography indicating that all coronary artery stenoses are <50%. (3) Experience angina-like symptoms after the angiography procedure despite taking prescribed as-needed medication. (4) No prior treatment with GXSC and no contraindications to its use.

Exclusion criteria

Exclusion criteria: (1) Non-atherosclerotic heart disease-related CMD: complicated with hypertrophic cardiomyopathy, dilated cardiomyopathy, aortic stenosis, heart failure with preserved ejection fraction, etc. (2) Complicated with severe congenital heart disease, rheumatic heart disease, severe arrhythmia, poorly controlled hypertension (systolic blood pressure =160 mmHg or diastolic blood pressure =100 mmHg), severe cardiac dysfunction (ejection fraction <30% or New York Heart Association functional class =III); (3) Complicated with trauma, acute infection, severe endocrine system diseases, hematopoietic system diseases, malignant tumors, and other system dysfunctions such as liver, brain, kidney, etc.; (4) Allergy to this drug or its known components; (5) History of surgery within the past month or those at risk of bleeding; (6) Mental illness or history of mental illness; (7) Other conditions deemed by the investigator as inappropriate for participation in this study.

Design outcomes

Primary

Measure	Time frame
Seattle Angina Questionnaire (SAQ);	—

Secondary

Measure	Time frame
Nitric oxide;High-sensitivity C-reactive protein;soluble intercellular adhesion molecule-1 ;	—

Countries

China

Contacts

Public ContactHaibing Wang

971 Hospital of the PLA Navy

sdwhb96@163.com13355327209

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: May 1, 2026